Apixaban Market Report 2026
Global Outlook – By Dosage Form (Capsule, Tablets), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)), By End-Users (Hospitals, Homecare, Specialty Clinics, Other End-Users) – Market Size, Trends, Strategies, and Forecast to 2030
Apixaban Market Overview
• Apixaban market size has reached to $3.16 billion in 2025 • Expected to grow to $4.61 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: Impact Of Cardiovascular Disease Prevalence On Apixaban Market Growth • Market Trend: Development Of Generic Anticoagulants Enhances Affordability And Expands Patient Access In The Apixaban Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Apixaban Market?
Apixaban is an oral anticoagulant medication that belongs to a class of drugs known as direct oral anticoagulants (DOACs). It is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, a type of irregular heartbeat. Apixaban is prescribed for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the prevention of DVT, which can lead to PE in patients who have undergone hip or knee replacement surgery. The main dosage forms of apixaban are capsules and tablets. Capsules are a dosage form where the medication is enclosed in a gelatin shell designed to be swallowed whole, allowing the capsule to dissolve in the digestive tract to release the active ingredient. Apixaban drugs are used in applications such as deep vein thrombosis (DVT) and pulmonary embolism (PE) by end users such as hospitals, home care, specialty clinics, and others.
What Is The Apixaban Market Size and Share 2026?
The apixaban market size has grown strongly in recent years. It will grow from $3.16 billion in 2025 to $3.43 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to growing prevalence of atrial fibrillation, increased awareness of stroke prevention, availability of generic anticoagulants, expansion of hospital infrastructure, advancements in diagnostic technologies.What Is The Apixaban Market Growth Forecast?
The apixaban market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising geriatric population, growing demand for minimally invasive surgeries, integration of digital health monitoring, innovation in oral anticoagulant formulations, expansion of homecare services. Major trends in the forecast period include increasing adoption of direct oral anticoagulants (doacs), rising incidence of cardiovascular disorders, expansion of post-surgical thromboprophylaxis programs, development of patient-centric anticoagulation therapies, growth in outpatient and homecare anticoagulant management.
Global Apixaban Market Segmentation
1) By Dosage Form: Capsule, Tablets 2) By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE) 3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-UsersWhat Is The Driver Of The Apixaban Market?
The rising prevalence of cardiovascular disease is expected to propel the growth of the apixaban market going forward. Cardiovascular disease encompasses a range of conditions affecting the heart and blood vessels, including coronary artery disease, stroke, and heart failure. The rising prevalence of cardiovascular disease is due to sedentary lifestyles, poor dietary habits, tobacco use, obesity, high blood pressure, diabetes, and aging populations. Apixaban is utilized in the management of cardiovascular disease by reducing the risk of blood clots by preventing conditions such as stroke, deep vein thrombosis, and pulmonary embolism. For instance, in January 2024, according to the American Heart Association, a US-based nonprofit organization, the number of deaths caused by cardiovascular diseases reached 931,578, an uptick of fewer than 3,000 fatalities compared to the 928,741 in 2023. Therefore, the rising prevalence of cardiovascular disease drives the growth of the apixaban industry.Key Players In The Global Apixaban Market
Major companies operating in the apixaban market are Bristol-Myers Squibb Company, Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Hetero Drugs Ltd., Medichem S.A., Simson Pharma Limited, Aspen Pharmacare Holdings Limited, Daiichi Sankyo Company Limited, Fresenius Kabi AG, Centaur Pharmaceuticals Pvt. Ltd., Pinnacle Life Sciences Private Limited
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Apixaban Market Trends and Insights
Major companies operating in the apixaban market are focusing on developing innovative solutions, such as generic anticoagulant medicines, to improve treatment affordability, broaden patient access, and strengthen their competitive positioning. Generic anticoagulant medicines are therapeutically equivalent formulations that prevent blood clot formation by inhibiting key factors in the coagulation cascade, thereby reducing the risk of stroke and other serious cardiovascular events. For instance, in February 2023, Zydus Lifesciences, an India-based pharmaceutical company, received final approval from the U.S. Food and Drug Administration (FDA) for its generic apixaban tablets in 2.5 mg and 5 mg strengths, the same strengths as the reference drug Eliquis. The approval enables wider availability of cost-effective anticoagulant therapy across the U.S. market, supporting improved patient access to essential treatments for conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism.What Are Latest Mergers And Acquisitions In The Apixaban Market?
In July 2025, Bristol-Myers Squibb Company, a US-based biopharmaceutical company that provides apixaban and develops prescription medications for serious diseases, partnered with Pfizer Inc. to offer a Direct-to-Patient option for Eliquis (apixaban). With this partnership, Bristol-Myers Squibb and Pfizer aim to leverage their respective expertise in pharmaceutical development and patient access, combining Bristol-Myers Squibb’s clinical and safety experience with Pfizer’s extensive distribution network to provide patients with a convenient home delivery option for Eliquis, ultimately improving medication adherence and patient outcomes. Pfizer Inc. is a US-based pharmaceutical company that researches, develops, and manufactures medicines and vaccines across a wide range of therapeutic areas.
Regional Insights
North America was the largest region in the apixaban market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Apixaban Market?
The apixaban market consists of sales of generic drugs, oral tablets and blister packs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Apixaban Market Report 2026?
The apixaban market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the apixaban industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Apixaban Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $3.43 billion |
| Revenue Forecast In 2030 | $4.61 billion |
| Growth Rate | CAGR of 8.5% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Dosage Form, Application, End-Users |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | Bristol-Myers Squibb Company, Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Hetero Drugs Ltd., Medichem S.A., Simson Pharma Limited, Aspen Pharmacare Holdings Limited, Daiichi Sankyo Company Limited, Fresenius Kabi AG, Centaur Pharmaceuticals Pvt. Ltd., Pinnacle Life Sciences Private Limited |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |